Loading
Life sciences · Journal article
Polymers · July 24, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a materials development study demonstrating that electrospun PLA/PCL membranes can incorporate rifampicin, remain stable, show biocompatibility in vitro using human immune cells, and sustain drug release for 72 hours in a mouse skin model while preserving antimicrobial activity. It establishes proof of concept but provides no evidence of efficacy in humans or therapeutic benefit in disease.
Uncontrolled in vitro proof-of-concept study. In vitro systems: primary human peripheral blood mononuclear cells and mouse skin tissue. No human subjects or animal models in vivo.. Intervention: Electrospun poly(lactic acid)/poly(ε-caprolactone) (PLA/PCL) membranes incorporating rifampicin for transdermal delivery.
Electrospun membranes achieved average fiber diameter of approximately 250 nm with efficient drug incorporation Membranes retained tensile strength and dimensional stability after accelerated temperature–humidity aging In vitro transdermal permeation demonstrated sustained rifampicin diffusion for at least 72 h using mouse skin model
No in vivo efficacy data in animals or humans; mouse skin is not predictive of human transdermal absorption or tolerability. Sample sizes for cytotoxicity and biocompatibility assays not reported; statistical significance testing not described.
This work is preclinical. While it supports the feasibility of a novel transdermal rifampicin platform, clinicians should await in vivo pharmacokinetic studies, human skin safety data, and controlled trials demonstrating therapeutic benefit or improved adherence before considering clinical adoption.
Proof-of-concept study demonstrating material feasibility and in vitro performance; lacks in vivo efficacy data, clinical outcomes, or human safety evidence needed to support clinical translation.
As stated by the source record.
Quoted from the source exactly as published.
This work is preclinical. While it supports the feasibility of a novel transdermal rifampicin platform, clinicians should await in vivo pharmacokinetic studies, human skin safety data, and controlled trials demonstrating therapeutic benefit or improved adherence before considering clinical adoption.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Poor adherence to prolonged antibiotic regimens remains a major challenge in the treatment and prevention of chronic infectious diseases such as tuberculosis. Transdermal drug delivery systems capable of sustained antibiotic release may improve therapeutic compliance while reducing the need for frequent oral administration. In this study, electrospun polymeric membranes based on poly(lactic acid) (PLA) and poly(ε-caprolactone) (PCL) were developed as transdermal rifampicin delivery platforms. Homogeneous nanofibrous membranes with average fiber diameters of approximately 250 nm were successfully fabricated and exhibited efficient drug incorporation while preserving the structural integrity of the polymeric matrix. The electrospun membranes retained sufficient tensile strength and dimensional stability after accelerated temperature–humidity aging, supporting their stability during storage, handling, and application. In vitro cytotoxicity and biocompatibility assays using primary human peripheral blood mononuclear cells (PBMCs) demonstrated that the developed systems did not induce significant cytotoxic or pro-inflammatory responses. Transdermal permeation studies using an in vitro mouse skin model demonstrated sustained rifampicin diffusion for at least 72 h. Importantly, the antibiotic recovered after skin permeation preserved antimycobacterial activity against Mycobacterium tuberculosis H37Ra and Mycobacterium bovis BCG, confirming that rifampicin maintained its biological functionality after electrospinning and transdermal migration. Overall, these findings demonstrate the potential of electrospun PLA/PCL membranes as stable and biocompatible transdermal antibiotic delivery systems capable of sustained release and preservation of antimicrobial activity. This proof-of-concept study supports the translational potential of electrospun polymeric platforms for controlled antibiotic delivery in long-term infectious disease therapies.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.